Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

Ola Landgren, Suzanne Trudel, Jacalyn Rosenblatt et al. Nov 03, 2025 pp. 4058-4058 10.1182/blood-2025-4058

Abstract Background Elranatamab (ELRA) is a bispecific antibody (BsAb) targeting B-cell maturation antigen (BCMA) on myeloma cells and CD3 on...

Systematic molecular profiling to identify determinants of response to ibrutinib

Negin Karisani, Amit Sud, Liang Li et al. Nov 03, 2025 pp. 3881-3881 10.1182/blood-2025-3881

Abstract BACKGROUND Whilst the broad clonal architecture of naturally progressing chronic lymphocytic leukemia (CLL) has been described, a co...

Trends and disparities in multiple myeloma mortality in the United States: A 25-year analysis from 1999 to 2023

Muhammad Zahid Anwar, hareem tahir, Zara Khan et al. Nov 03, 2025 pp. 4594-4594 10.1182/blood-2025-4594

Abstract Introduction Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells within bone...

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Pengpeng Xu, Hongmei Jing, Songfu Jiang et al. Nov 03, 2025 pp. 3689-3689 10.1182/blood-2025-3689

Abstract Introduction: Diffuse large B cell lymphoma (DLBCL) is genetically heterogenous, comprising distinct molecular subtypes (MCD, BN2, N...

Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML

Aleksej Drino, Artur Speiser, Peter Kovacs-Hajdu et al. Nov 03, 2025 pp. 1716-1716 10.1182/blood-2025-1716

Abstract Background Selecting the optimal therapy in acute myeloid leukemia (AML) can be clinically challenging—particularly for patients wi...

Efficacy and safety of the LSD1 inhibitor bomedemstat in participants with polycythemia vera (PV) resistant or intolerant to cytoreductive therapy: The Phase 2 shorespan-004 study

Lindsay Rein, Alice Livings, Rebecca Frewin et al. Nov 03, 2025 pp. 83-83 10.1182/blood-2025-83

Abstract Introduction: PV is a JAK2-driven myeloproliferative neoplasm (MPN) characterized by an erythroid dominant trilineage proliferation...

Major bleeding and stroke in patients with hemophilia and atrial fibrillation

Walker Schmidt, Rajiv Pruthi, Leslie Padrnos Nov 03, 2025 pp. 1299-1299 10.1182/blood-2025-1299

Abstract Background Congenital hemophilias affect about 30,000 US individuals (0.01% of the population) and atrial fibrillation (AF) about 1...

Global assessment of patient and caregiver unmet needs in myeloproliferative neoplasms (MPNs): Findings from the 2024 international assessment

Sara Douglas, David Shoultz, Amielle Moreno et al. Nov 03, 2025 pp. 966-966 10.1182/blood-2025-966

Abstract Background Despite therapeutic advances, patients with myeloproliferative neoplasms (MPNs) continue to face sig...

Revisiting the therapeutic potential of fenretinide in acute erythroid and acute megakaryoblastic leukemias

Manal Elmasry, Yasharah Raza, Zhan Rong et al. Nov 03, 2025 pp. 6804-6804 10.1182/blood-2025-6804

Abstract N-(4-hydroxyphenyl)retinamide (4-HPR, also known as Fenretinide) is a synthetic derivative of vitamin A with well-established anti-...

Cost-effectiveness of CAR-T cell therapy compared to bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A retrospective study using a markov model

Harry Balanta Murcia, James Ignatz-Hoover, Nikki Agarwal Nov 03, 2025 pp. 4423-4423 10.1182/blood-2025-4423

Abstract Introduction: Multiple myeloma (MM) is considered an incurable malignancy, but with modern therapies, patients can achieve deep and...

Correlation of antral follicle count and antimullerian hormone in women with sickle cell disease

Lydia Pecker, Vinal Menon, Lauren Anthony et al. Nov 03, 2025 pp. 4729-4729 10.1182/blood-2025-4729

Abstract Background: Ovarian reserve is compromised in adults with sickle cell disease (SCD), but whether SCD treatment exposures drive this...

Safety and preliminary efficacy of combined lenalidomide and CD19 CAR T-cell therapy in relapsed/refractory CLL: A phase I study

Mikalai Katsin, Dmitri Dormeshkin, Alexandr Migas et al. Nov 03, 2025 pp. 2371-2371 10.1182/blood-2025-2371

Abstract Introduction Despite the clinical efficacy of CD19 CAR-T cells in Non-Hodgkin lymphomas, the clinical efficacy of CD19 CAR T-cell t...

The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma

Selene Mallia, Giulia Gambarelli, Veronica Manicardi et al. Nov 03, 2025 pp. 1477-1477 10.1182/blood-2025-1477

Abstract Transcription and replication both utilize genomic DNA as a template, creating the potential for frequent interference between the...

Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase Ⅰ/Ⅱ study in relapsed/refractory multiple myeloma

Bin Fan, Juanjuan Wu, Jin Lu et al. Nov 03, 2025 pp. 4070-4070 10.1182/blood-2025-4070

Abstract Introduction: LBL-034 is a humanized IgG1 subtype asymmetric bispecific antibody targeting GPRC5D and CD3 with a 2:1 format. Its aff...

Exploring co-mutations in CML and ph(+) b-ALL with ABL1 variants: Correlations with survival and treatment response.

Kaitlyn Dykes, Nicholas Protopsaltis, James Mangan et al. Nov 03, 2025 pp. 3777-3777 10.1182/blood-2025-3777

Abstract Introduction: The impact of co-mutations seen with ABL1 kinase domain mutations is unclear in today's treatment landscape (Branford...

Replication fork remodeling is a therapeutic vulnerability in acute myeloid leukemia

Cyril Dördelmann, Tsz Kan Fung, Tristan Gasparetto et al. Nov 03, 2025 pp. 5016-5016 10.1182/blood-2025-5016

Abstract Objectives: Acute myeloid leukemia (AML) is mostly driven by specific mutations that affect transcription factors and epigenetic re...

Cardiopulmonary complications of DIC in AML: A nationwide inpatient study

Ridda Khattak, Rohab Sohail, Zaraq Khan et al. Nov 03, 2025 pp. 3412-3412 10.1182/blood-2025-3412

Abstract Background: Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, accounting for approximately 80% of ad...

Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.

Andy Rawstron, David Cairns, Nichola Webster et al. Nov 03, 2025 pp. 794-794 10.1182/blood-2025-794

Abstract Introduction: The FLAIR (ISRCTN01844152) phase III trial for previously untreated fit CLL patients showed that measurable residual...

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Alex Herrera, Michael LeBlanc, Sharon Castellino et al. Nov 03, 2025 pp. 151-151 10.1182/blood-2025-151

Abstract Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients (pts) with previously untreate...

Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre

Anca Prica, Antonette Pillainayagam, Manjula Maganti et al. Nov 03, 2025 pp. 4530-4530 10.1182/blood-2025-4530

Abstract Introduction Chimeric Antigen Receptor T-Cell (CAR-T) therapy has become the preferred treatment for patients w...

Influence of air quality on clinical acuity at presentation in pediatric patients with newly diagnosed Acute Myeloid Leukemia

Alexis Boulter, Quynh Long Khuong, Vicky Tam et al. Nov 03, 2025 pp. 2848-2848 10.1182/blood-2025-2848

Abstract Introduction: Clinical acuity at presentation is a predictor of mortality and a mediator of racial disparities in early mortality i...

Complement inhibition in post-transplant IgA-mediated autoimmune cytopenia: A pediatric case report

Braden Olsen, Melanie Everitt, Taizo Nakano et al. Nov 03, 2025 pp. 6437-6437 10.1182/blood-2025-6437

Abstract Background: Autoimmune hemolytic anemia (AIHA) is a well-described complication in pediatric populations and solid organ transplant...

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Zachary Epstein-Peterson, Marina Gomez-Llobell, Vanisha Patel et al. Nov 03, 2025 pp. 2710-2710 10.1182/blood-2025-2710

Abstract Purpose: Mantle cell lymphoma (MCL) predominantly affects older adults, who may be ineligible for intensive therapies. Limited data...

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Aseel Alsouqi, Ying Huang, Lindsey Rike et al. Nov 03, 2025 pp. 1953-1953 10.1182/blood-2025-1953

Abstract Richter transformation (RT) occurs in ~4% of patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL) and is as...

Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions

Mark-David Levin, Sabina Kersting, Kazem Nasserinejad et al. Nov 03, 2025 pp. 3897-3897 10.1182/blood-2025-3897

Abstract Introduction In the HOVON 139/GiVe trial previously untreated CLL patients unfit for FCR received 2 cycles of obinutuzumab monothera...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page